Treatment Perspectives for Ovarian Cancer in Europe and the United States: Initial Therapy and Platinum-Sensitive Recurrence after PARP Inhibitors or Bevacizumab Therapy

被引：0
|
作者：
Alexandra Lainé
Travis T. Sims
Olivia Le Saux
Isabelle Ray-Coquard
Robert L. Coleman
机构：
[1] University Claude Bernard Lyon I,Centre Léon Bérard
[2] The University of Texas MD Anderson Cancer Center,Department of Gynecologic Oncology and Reproductive Medicine
[3] US Oncology Research,Gynecologic Oncology
来源：
Current Oncology Reports | 2021年 / 23卷
关键词：
Ovarian cancer; Platinum-sensitive; PARP inhibitors; Anti-angiogenic; Maintenance therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Treatment Perspectives for Ovarian Cancer in Europe and the United States: Initial Therapy and Platinum-Sensitive Recurrence after PARP Inhibitors or Bevacizumab Therapy
    Laine, Alexandra
    Sims, Travis T.
    Le Saux, Olivia
    Ray-Coquard, Isabelle
    Coleman, Robert L.
    [J]. CURRENT ONCOLOGY REPORTS, 2021, 23 (12)
  • [2] Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis
    Bartoletti, Michele
    Pelizzari, Giacomo
    Gerratana, Lorenzo
    Bortot, Lucia
    Lombardi, Davide
    Nicoloso, Milena
    Scalone, Simona
    Giorda, Giorgio
    Baldassarre, Gustavo
    Sorio, Roberto
    Puglisi, Fabio
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (11)
  • [3] Recurrence patterns after bevacizumab in platinum-sensitive, recurrent epithelial ovarian cancer
    Kim, Se Ik
    Lee, Eun Ji
    Lee, Maria
    Chung, Hyunhoon
    Kim, Jae-Weon
    Park, Noh Hyun
    Song, Yong-Sang
    Kim, Hee Seung
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 (12) : 1943 - 1950
  • [4] Treatment strategy for patients with platinum-sensitive ovarian cancer using PARP inhibitors
    Matsumoto, Koji
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [5] SEARCHING FOR THE BEST MAINTENANCE THERAPY IN PLATINUM-SENSITIVE RECURRENT OVARIAN CANCER: BEVACIZUMAB OR PARP-INHIBITORS? A NETWORK META-ANALYSIS
    Bartoletti, M.
    Pelizzari, G.
    Bortot, L.
    Giavarra, M.
    Vitale, M. G.
    Andreotti, V.
    Parnofiello, A.
    Scalone, S.
    Lombardi, D.
    Nicoloso, M.
    Bozza, C.
    Poletto, E.
    Sacco, C.
    Andreetta, C.
    Sorio, R.
    Puglisi, F.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A437 - A438
  • [6] PARP inhibitors as maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: Can we afford it?
    Smith, H. J.
    Haygood, C. L. Walters
    Arend, R. C.
    Leath, C. A., III
    Straughn, J. M., Jr.
    [J]. GYNECOLOGIC ONCOLOGY, 2015, 137 : 9 - 9
  • [7] PARP INHIBITORS MAINTENANCE THERAPY IN PLATINUM-SENSITIVE RELAPSED OVARIAN CANCER: A COMPREHENSIVE CANCER CENTRE'S EXPERIENCE
    Moreira, I.
    Ferreira, M.
    Lopes, A. R.
    Savva-Bordalo, J.
    Abreu, M.
    Sousa, S.
    Pereira, D.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A239 - A239
  • [8] Bevacizumab or PARP-inhibitors maintenance therapy for platinum-sensitive (PS) recurrent ovarian cancer (rOC)? A network meta-analysis (NMA).
    Bartoletti, Michele
    Pelizzari, Giacomo
    Gerratana, Lorenzo
    Garattini, Silvio Ken
    Basile, Debora
    Lisanti, Camilla
    Bortot, Lucia
    Corvaja, Carla
    Garutti, Mattia
    Scalone, Simona
    Nicoloso, Milena
    Bolzonello, Silvia
    Torrisi, Elena
    Da Ros, Lucia
    Di Nardo, Paola
    Lombardi, Davide
    Giorda, Giorgio
    Baldassarre, Gustavo
    Sorio, Roberto
    Puglisi, Fabio
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [9] Front-line maintenance therapy for platinum-sensitive ovarian cancer: What's next PARP inhibitors?
    Gong, H.
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [10] A Cost-Effectiveness Analysis of Three PARP Inhibitors for Maintenance Therapy in Platinum-Sensitive Recurrent Ovarian Cancer
    Liu, A. Y.
    Cohen, J. G.
    Walsh, C. S.
    Holschneider, C. H.
    Sinno, A. K.
    [J]. GYNECOLOGIC ONCOLOGY, 2017, 147 (01) : 196 - 196
12345